INM Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	476 022
Średni wolumen	382 840
Kapitalizacja rynkowa	1.39M
EPS	$0 ( 2024-02-16 )
Następna data zysków	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.550
ATR14	$0.00400 (1.74%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-14	Hull Andrew	Sell	42	Employee Stock Option (Expiration)
2024-03-04	Hsu Eric C	Sell	309	Employee Stock Option (Expiration)
2024-01-21	Mancini Alexandra Diane Janet	Sell	121	Employee Stock Option (Expiration)
2024-02-20	Jagpal Netta	Sell	50 000	Employee Stock Option (Right to Buy)
2024-02-21	Hull Andrew	Buy	37 500	Common Stock

INSIDER POWER
74.61
Last 93 transactions
Buy: 1 291 573 \| Sell: 391 310

Wolumen Korelacja

Długi: -0.25 (neutral)

Krótki: 0.53 (weak)

Signal:(43.503) Neutral

InMed Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
ZSAN	0.901
KBSF	0.889
BNOX	0.885
ARQQ	0.884
AYLA	0.884
VIH	0.884
LYRA	0.882
QLGN	0.881
LQDT	0.879
DWACU	0.87

10 Najbardziej negatywne korelacje
STAY	-0.89
AVGO	-0.884
TIPT	-0.883
BNIXU	-0.876
TVTY	-0.875
ARDX	-0.874
USLM	-0.872
LRFC	-0.869
LUNA	-0.864
PEBK	-0.862

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

InMed Pharmaceuticals Korelacja - Waluta/Towar

0.00
( neutral )

0.43
( neutral )

0.00
( neutral )

0.10
( neutral )

InMed Pharmaceuticals Finanse

Annual	2023
Przychody:	$4.14M
Zysk brutto:	$1.40M (33.93 %)
EPS:	$-3.25

FY	2023
Przychody:	$4.14M
Zysk brutto:	$1.40M (33.93 %)
EPS:	$-3.25

FY	2022
Przychody:	$1.09M
Zysk brutto:	$543 546 (49.89 %)
EPS:	$-41.74

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-38.00

Financial Reports:

No articles found.

InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.